Melanoma Immunotherapy and Precision Medicine — a Medical Student’s Perspective

By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 20 January 2017 In Science

Malignant melanoma research has provided the perfect opportunity to explore the intersection of immunotherapy and precision medicine, which has greatly transformed melanoma therapeutics in the last decade.

Read More


Tara's Story

By Pamela Goldsmith, MRA Director of Communications | 20 January 2017 In Melanoma Stories

To say that Tara Miller inspired mixed emotions is to begin to understand her life. The strong-willed survivor, who lost her battle to melanoma in 2014, reflected the contradictions that define an indomitable will to live.

Read More


Parallels between Disease States

By Michael Kaplan, MRA President & CEO | 30 November 2016 In Science

Six months ago I was offered the opportunity to serve as President & CEO of MRA and in July, I officially began. For the past 24 years, I’ve worked in the HIV field and am struck by the many parallels that exist between my past work and melanoma.

Read More


Uncommon Immunotherapy Side Effects

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016

A recent report in the prestigious New England Journal of Medicine (NEJM), has spawned reports like this one, regarding the risk of death in patients treated with combination checkpoint treatments. The first author of the NEJM story is MRA-funded investigator, Doug Johnson at Vanderbilt.

Read More


Championing Collaboration

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016

Some have the impression that cancer researchers, whether in academia or in industry, toil away in isolation. While there are certainly scientists who work best on their own, collaboration among researchers has become increasingly common, with a goal of achieving the most promising results in the shortest time frame.

Read More


MRA Funded Melanoma Researchers Led Discussions at 2016 Annual Meeting of the Society for Immunotherapy of Cancer

By Pamela Goldsmith, MRA Director of Communications | 30 November 2016

MRA Director of Communications Melanoma Research Alliance (MRA) investigators and other melanoma researchers had a significant presence at this year’s annual meeting of the Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. A key forum for scientific exchange and enlightenment in the cancer immunotherapy field, the conference...

Read More



To Screen or Not to Screen (for Skin Cancer) – Reframing the Question

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 29 July 2016

To screen or not to screen actually isn’t the question  While an adaptation of Hamlet’s famous phrase may capture the headlines on whole-body skin checks, a deeper dive gets us closer to questions of life and death.

Read More


Highlights from the National Cancer Moonshot Summit

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 7 July 2016 In Events, News

The National Cancer Moonshot was announced by President Obama in his State of the Union Address in January 2016 and VP Biden was charged with spearheading the effort. Few would disagree with Mr. Biden’s selection as leader given the personal experience he and his family endured with the loss of...

Read More


Understanding Immunotherapy Part 3: CTLA-4

By Amrita Bhatt, MRA Intern | 15 June 2016 In Science, Treatment

Now that you’ve read our background on immunotherapy and learned about PD-1, it’s time to focus on another protein that plays a key role in cancer development, CTLA-4. What is CTLA-4? In addition to displaying PD-1 on the cell surface, T cells also display CTLA-4.

Read More


Login

×